Why Cathie Wood Is Buying AMD and Selling CRISPR Stocks: A Closer Look at ARK’s Latest Moves
Have you ever wondered what the big market players are doing with their money? Let’s talk about one of the most closely watched investors out there—Cathie Wood—and the bold moves her firm, ARK Invest, is making.
In the ever-changing world of investing, ARK Invest’s daily trades often give us insights into where innovation may be heading. So, when Cathie Wood buys shares of one company and sells another, it’s worth paying attention.
Recently, her firm made a big shift—increasing investment in Advanced Micro Devices (AMD) and cutting back exposure to CRISPR Therapeutics (CRCL). Let’s break down what this could mean and why it matters to everyday investors like you and me.
Big Move: ARK Invest Buys More AMD Stock
Advanced Micro Devices, better known as AMD, is a tech company that develops computer processors and related technologies. It competes with giants like Intel and NVIDIA. Recently, ARK Invest added 78,544 shares of AMD across three of its ETFs:
- ARK Innovation ETF (ARKK)
- ARK Fintech Innovation ETF (ARKF)
- ARK Next Generation Internet ETF (ARKW)
So, why is ARK piling into AMD now?
The answer lies in AMD’s growing role in AI and high-performance computing. With the surge in AI tools and machine learning applications (yes, like ChatGPT), AMD’s chips are becoming more valuable. Investing in AMD could mean you’re betting on the future of artificial intelligence itself.
AMD Stock Purchase Breakdown
Here’s how the numbers looked on the day of the trade:
| ETF Name | Number of AMD Shares Bought |
|---|---|
| ARK Innovation ETF (ARKK) | 41,871 |
| ARK Next Generation Internet ETF (ARKW) | 19,146 |
| ARK Fintech Innovation ETF (ARKF) | 17,527 |
In total, ARK bought over $11 million worth of AMD. That’s a serious vote of confidence.
Cutting Back: ARK Reduces Position in CRISPR Therapeutics
While loading up on AMD shares, ARK also made a surprising move—selling 188,395 shares of CRISPR Therapeutics (CRCL). CRCL is known for using gene-editing technology to fight diseases. Sounds futuristic, right?
It is. But investing is all about timing and rebalancing risk. And lately, CRISPR-related stocks have struggled, especially with FDA reviews and delays creating uncertainty in the biotech space.
Here’s a look at where ARK sold those shares:
| ETF Name | Number of CRISPR Shares Sold |
|---|---|
| ARK Innovation ETF (ARKK) | 57,007 |
| ARK Next Generation Internet ETF (ARKW) | 3,882 |
| ARK Genomic Revolution ETF (ARKG) | 127,506 |
While Wood has long been bullish on biotech and genomics, this large-scale reduction hints that the firm is possibly tightening its focus on fewer high-conviction bets—or simply reallocating to higher-growth opportunities like AI.
What’s Driving These Trades?
At first glance, it might seem like ARK is just shuffling stocks. But there’s a strategic pattern here. Think of it like managing a fantasy sports team. You keep the players that are in form and bench those who are underperforming—for now.
In Cathie Wood’s case, she appears to be shifting focus from long-term moonshots like gene editing to technologies that are making a more immediate impact—like AMD’s AI hardware. That’s a tactical move driven by real-time performance and market sentiment.
And it’s not just about individual stocks—it’s about entire sectors. The AI boom is driving tech stocks higher, while biotech, especially small-cap firms like CRISPR Therapeutics, are facing regulatory challenges and slower growth expectations.
What This Could Mean for Everyday Investors
You might be wondering: “So, what should I do?” First things first—this isn’t investment advice. But analyzing moves by ARK Invest can be a great window into emerging trends and market confidence.
Here are some key takeaways:
- Tech and AI are hot right now. AMD’s rising popularity shows investor appetite isn’t cooling down yet.
- Biotech may still be promising, but it’s risky and slow-moving. ARK scaling back exposure to CRISPR shows caution in that space.
- Diversification matters. ARK spreads these trades across multiple ETFs, which helps manage risk.
If you’re building your own portfolio, consider how much you’re exposed to future tech versus stable, income-generating assets. And remember, even bold investors like Cathie Wood pivot based on data and changing conditions.
Final Thoughts: Keep Learning from the Pros
One thing I always admire about Cathie Wood is her willingness to act boldly even when the market zigs while she zags. Whether you agree with her moves or not, there’s value in watching how professionals think and shift their strategies.
Think of your financial journey like steering a ship. Some days are calm, others are stormy. Watching what investor “captains” like Cathie Wood do in different market weather can help you prepare your sails!
So, next time you see a news headline about ARK buying AMD or selling CRISPR, don’t just scroll past it. Dig a little deeper—it might teach you something new about where the world (and your money) is headed.
Until next time, happy investing—and stay curious!
Related Keywords You Might Be Interested In:
- ARK Invest daily trades
- Cathie Wood stock picks 2024
- AMD stock analysis
- CRISPR Therapeutics news
- Best AI stocks to watch
Disclaimer: This post is for informational purposes only and does not constitute financial advice. Always do your own research or consult a licensed advisor before making investment decisions.